Wells Fargo & Company Lowers Affimed (NASDAQ:AFMD) Price Target to $15.00

Affimed (NASDAQ:AFMD) had its target price cut by research analysts at Wells Fargo & Company from $20.00 to $15.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently commented on AFMD. Stifel Nicolaus decreased their target price on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a report on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Affimed in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Affimed Stock Performance

Shares of AFMD stock opened at $2.15 on Thursday. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a fifty-two week low of $2.02 and a fifty-two week high of $8.95. The stock has a 50 day moving average price of $3.08 and a two-hundred day moving average price of $4.17.

Institutional Investors Weigh In On Affimed

A number of institutional investors have recently modified their holdings of AFMD. Jane Street Group LLC purchased a new stake in shares of Affimed in the third quarter worth $44,000. Choreo LLC purchased a new stake in shares of Affimed during the second quarter valued at $54,000. FMR LLC boosted its position in shares of Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares during the last quarter. Intellectus Partners LLC boosted its position in shares of Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 10,250 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its position in shares of Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 15,108 shares during the last quarter. 30.82% of the stock is owned by hedge funds and other institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.